Large-scale testing (Phase 3)Study completedNCT02822794
What this trial is testing
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Who this might be right for
Hepatitis C Virus Infection
Gilead Sciences 117